Agios Crystalline Salt Forms of Quinolinesulfonamide - EP3972957A1
Summary
The European Patent Office published application EP3972957A1 on 15 April 2026, covering crystalline salt forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide. Agios Pharmaceuticals, Inc. is the applicant, with Lisa M. Grove listed as inventor. The application covers the pharmaceutical compound classified under C07D 215/36, A61P 7/06, and A61K 31/4709, with designated states spanning across European member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 49 changes logged to date.
What changed
The EPO published patent application EP3972957A1 for crystalline salt forms of a quinolinesulfonamide compound belonging to Agios Pharmaceuticals, Inc. The application names Lisa M. Grove as inventor and covers pharmaceutical compositions classified under C07D 215/36, A61P 7/06, and A61K 31/4709. Designated states include all European patent convention member states across the EU.
Pharmaceutical companies and biotech firms engaged in drug development or licensing activities should review this publication to assess potential freedom-to-operate considerations or licensing opportunities related to this salt form technology. Generic pharmaceutical manufacturers and competitors in the oncology or hematology space may also find this relevant for patent monitoring and competitive intelligence purposes.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CRYSTALLINE SALT FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
Publication EP3972957A1 Kind: A1 Apr 15, 2026
Applicants
Agios Pharmaceuticals, Inc.
Inventors
GROVE, Lisa M.
IPC Classifications
C07D 215/36 20060101AFI20201127BHEP A61P 7/06 20060101ALI20201127BHEP A61K 31/4709 20060101ALI20201127BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.